Paul, Weiss is widely recognized as having one of the nation’s preeminent securities litigation and regulatory practices. For two decades, our lawyers have guided global corporations and financial institutions through a series of “bet-the-company” securities-related crises, consistently reducing or eliminating their most damaging claims and negotiating favorable resolutions.
Pleading and Proving "Loss Causation" After Dura Pharmaceuticals: What's Happening in the Lower Courts?
December 12, 2005 Full PDF
Attached is a copy of a new article by Paul, Weiss litigation partner Richard Rosen titled "Pleading and Proving 'Loss Causation' After Dura Pharmaceuticals: What's Happening in the Lower Courts?" The article was published in the December 12 Securities Regulation and Law Report, published by BNA. The article discusses the implications of the Supreme Court's recent decision in Dura Pharmaceuticals, Inc. v. Broudo, summarizes the emerging post-Dura case law, identifies the key trends and areas of controversy and also offers recommendations to defense counsel contemplating a motion based on Dura and its progeny. The attached article was reproduced with permission from Securities Regulation & Law Report, Vol. 37, No. 48 (Dec. 12, 2005). Copyright 2005 by The Bureau of National Affairs, Inc. (800-372-1033)